Kingsview Wealth Management LLC Sells 177 Shares of Becton, Dickinson and Company (NYSE:BDX)

Kingsview Wealth Management LLC decreased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 4.1% during the third quarter, HoldingsChannel reports. The firm owned 4,142 shares of the medical instruments supplier’s stock after selling 177 shares during the quarter. Kingsview Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $999,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of BDX. Livelsberger Financial Advisory purchased a new stake in Becton, Dickinson and Company in the third quarter worth about $26,000. Ashton Thomas Securities LLC bought a new position in shares of Becton, Dickinson and Company in the 3rd quarter worth approximately $33,000. Tompkins Financial Corp raised its position in shares of Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 46 shares in the last quarter. Sound Income Strategies LLC lifted its stake in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the period. Finally, Opal Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company during the second quarter valued at approximately $45,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Evercore ISI increased their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Raymond James decreased their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Price Performance

BDX opened at $224.20 on Wednesday. The firm has a market cap of $64.80 billion, a PE ratio of 37.74, a P/E/G ratio of 1.67 and a beta of 0.43. The stock has a 50-day moving average price of $234.83 and a 200-day moving average price of $234.40. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $249.89. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period in the previous year, the company earned $3.42 earnings per share. Sell-side analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be given a $1.04 dividend. The ex-dividend date of this dividend is Monday, December 9th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a yield of 1.86%. Becton, Dickinson and Company’s dividend payout ratio is 70.03%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.